DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
AD1166364
Title:
NY-ESO-1-specific TCR-engineered T-cell Immunotherapy for Triple Negative Breast Cancer
Report Date:
2021-10-01
Abstract:
Triple negative breast cancer (TNBC) is the most aggressive and difficultly treated subtype of metastatic breast cancer, with very limited treatment option due to lack of expression of estrogen receptors (ERs), progesterone receptors (PRs), or human epidermal growth factor receptor 2 (HER2). Cancer immunotherapy is becoming a promising approach for cancer treatment with little or controllable side effect. We hypothesize that treatment of TNBC patients with NY-ESO-1 TCR-transduced T cells is safe and will result in tumor regression and clinical benefits.
Document Type:
Conference:
Journal:
Pages:
26
File Size:
1.98MB
W81XWH-16-1-0418
(W81XWH1610418);
Contracts:
Grants:
Distribution Statement:
Approved For Public Release
